Humanised monoclonal antibody therapy for rheumatoid arthritis

doi:10.1016/0140-6736(92)92294-P

The Lancet

Volume 340, Issue 8822, 26 September 1992, Pages 748-752

https://doi.org/10.1016/0140-6736(92)92294-P Get rights and content

Abstract

Monoclonal antibodies that target T cells have shown some benefit in rheumatoid arthritis although responses have not been long lasting. This is partly due to insufficient therapy consequent upon antibody immunogenicity. Use of humanised antibodies, which are expected to be less foreign to man than conventional rodent antibodies, might overcome this problem. We therefore assessed in a phase 1 open study the potential of a "lymphocyte depleting" regimen of the humanised monoclonal antibody CAMPATH-1H in 8 patients with refractory rheumatoid arthritis.

Apart from symptoms associated with first infusions of antibody, adverse effects were negligible. Significant clinical benefit was seen in 7 patients, lasting for eight months in 1. After one course of therapy, there was no measurable antiglobulin response, although 3 out of 4 patients have become sensitised on retreatment.

Humanisation reduces the immunogenicity of rodent antibodies but anti-idiotype responses may still be seen on repeated therapy, even in patients sharing immunoglobulin allotype with the humanised antibody.

References (23)

Sp Cobbold et al.
A simple method for measuring patient anti-globulin responses against isotypic or idiotypic determinants
J Immunol Methods
(1990)
G. Hale et al.
Removal of T cells from bone marrow for transplantation: a monoclonal anti-lymphocyte antibody that fixes human complement
Blood
(1983)
J. Prinz et al.
Chimaeric CD4 monoclonal antibody in treatment of generalised pustular psoriasis
Lancet
(1991)
J. Emmrich et al.
Treatment of inflammatory bowel disease with anti-CD4 monoclonal antibody
Lancet
(1991)
H. Waldmann
Manipulation of T-cell responses with monoclonal antibodies
Annu Rev Immunol
(1989)
Ra Watts et al.
Immunotherapy of rheumatoid arthritis
Ann Rheumatol
(1992)
Jd Isaacs
The antiglobulin response to therapeutic antibodies
Semin Immunol
(1990)
L. Riechmann et al.
Reshaping human antibodies for therapy
Nature
(1988)
Sd Gorman et al.
Humanisation of monoclonal antibodies for therapy
Semin Immunol
(1990)
G. Hale et al.
The CAMPATH-1 antigen (CDw52)
Tissue Antigens
(1990)

Ah Puttick et al.

Genes associated with rheumatoid arthritis and mild inflammatory arthritis. II. Association of HLA with complement C3 and immunoglobulin Gm allotypes

Ann Rheum Dis

(1990)

Cited by (306)

Immune monitoring of patients treated with anti-CD20 therapeutic monoclonals for autoimmune disorders
2023, Resistance to Anti-CD20 Antibodies and approaches for their Reversal: Volume 2
Immunosuppression has been centered on T cells, due to their role in allo- and autoimmunity. Patients on rituximab for lymphomas improve their concomitant rheumatoid arthritis, highlighting the role of B cells in autoimmunity. B cells differentiate from precursors to antibody-secreting plasma cells. CD20 is expressed from pre-B to mature activated memory B cells. By eliminating CD20+ cells, naïve precursors initially devoid of autoreactivity and long-living plasma cells are spared. Rituximab aims at eliminating the B cell memory of pathogenic IgG autoantibodies, hoping that this has not proceeded to autoreactive CD20− plasma cells.
Rituximab is approved for rheumatoid arthritis, polyangiitis, and pemphigus, but is successfully used in the off-label treatment of almost all autoimmune disorders. Therapeutic antibodies offer the opportunity to monitor their effects on cell targets, the disappearance and reappearance of the relevant cells, and to evidence deviations from the expected patterns. The ISCCA flow protocol has been devised to monitor and optimize the treatment schemes, to identify treatment-resistant patients, to evaluate the B cell repopulation, and to prevent overimmunosuppression. This protocol allows the high-sensitivity analysis of very small B cell subsets during the depletion and repopulation phases. In anti-CD20 treated autoimmune diseases, the early and long-lasting disappearance of B cells, the slow repopulation by naïve CD27− B cells, and the reduced memory of CD27+ IgG+ B cells are indicators of good response. The commitment of IgG-switched memory B cells to plasma cells can be also evaluated. Limitations of the monitoring of the functional B cell subsets in peripheral blood are, however, present and discussed. Despite the high individual and disease-related variability, the ISCCA protocol is of help in the management of anti-CD20 treatments in autoimmune disorders, in case of escape phenomena, disease relapses, and overimmunosuppression.
Modulating T-cell activation with antisense oligonucleotides targeting lymphocyte cytosolic protein 2
2022, Journal of Autoimmunity
Dysregulated T-cell activation is a hallmark of several autoimmune diseases such as rheumatoid arthritis (RA) and multiple sclerosis (MS). The lymphocyte cytosolic protein 2 (LCP2), also known as SLP-76, is essential for the development and activation of T cells. Despite the critical role of LCP2 in T-cell activation and the need for developing drugs that modify T-cell activation, no LCP2 inhibitors have been developed. This can be explained by the “undruggable” nature of LCP2, lacking a structure permissive to standard small molecule inhibitor modalities. Here, we explored an alternative drug modality, developing antisense oligonucleotides (ASOs) targeting LCP2 mRNAs, and evaluated its activity in modulating T-cell activation. We identified a set of 3′ UTR targeting LCP2 ASOs, which knocked down LCP2 in a human T-cell line and primary human T cells and found that these suppressed T-cell receptor mediated activation. We also found that the ASOs suppressed FcεR1-mediated mast cell activation, in line with the role of LCP2 in mast cells. Taken together, our data provide examples of how immunomodulatory ASOs that interfere with undruggable targets can be developed and propose that such drug modalities can be used to treat autoimmune diseases.
Alemtuzumab in renal transplantation. Reviews of literature and usage in the United Kingdom
2022, Transplantation Reviews
Citation Excerpt :
Over the subsequent years, Campath 1H was trialed in bone marrow transplants worldwide [24]. In 1988, Campath was evaluated for the treatment of patients with non-Hodgkin's lymphoma and vasculitis [28,29], and in 1991, studies were carried out in patients with rheumatoid arthritis and multiple sclerosis [30,31]. Further studies were also carried out in patients with chronic lymphocytic leukaemia (CLL) [32].
Kidney transplantation has evolved over the years from transplants between identically matched donors and recipients to successfully transplanting allografts across virtually any degree of donor-recipient human leukocyte antigen mismatch and ABO-incompatibility. Integral to these improved outcomes has been the development and deployment of a range of immunosuppressive agents. The addition of monoclonal and polyclonal antibodies as a standard part of overall immunosuppression has led to the improved outcomes by providing a robust and focused protection during the first few months of transplantation when allografts are most vulnerable to immune-mediated injury.
Alemtuzumab is a recombinant anti-CD52 pan-lymphocyte depleting monoclonal antibody that has been in use for kidney transplantation since the late 1990s.
Despite the many years of experience with alemtuzumab, its utilisation in the UK has remained relatively restrained. This may be due to a lack of high-level evidence to support its safety and efficacy in transplantation. Also, long-term outcomes have not been addressed by existing studies.
Nevertheless, available evidence suggests that alemtuzumab is associated with a lower risk of acute rejection within the first year of transplantation while exhibiting a comparable safety profile to non-lymphocyte depleting agents. Despite the current economic advantages of alemtuzumab (available free of cost on a named transplant recipient basis), its use in UK transplant centres has remained limited, variating from non-use, through usage in selected high immunologic risk subjects, to use as routine induction immunosuppression.
This review discusses the current use of alemtuzumab for immunosuppression induction in kidney transplantation. It describes its evolution from development to its present application in kidney transplantation and reviews the evidence underpinning its utilisation. The role of alemtuzumab in the immunosuppressive protocols individual UK kidney transplant centres is also described.
Tolerance-inducing medicines in autoimmunity: rheumatology and beyond
2020, The Lancet Rheumatology
Citation Excerpt :
Following renal transplantation, the addition of a rodent IgM CD52 mAb (Campath-1M) to standard immunosuppression reduced acute cellular rejection but increased serious infection risk.37 Studies of alemtuzumab (humanised Campath-1H) in rheumatoid arthritis suggested therapeutic benefit for some participants, often lasting for 6 months or longer after a brief course of therapy.38,39 These trials were curtailed largely because of chronic therapy-induced lymphopenia.
Autoimmunity is currently managed with generalised immunosuppression, which is associated with serious side-effects such as infection and cancer. An ideal treatment strategy would be to induce immune tolerance—ie, to reprogramme the immune system to stop recognising the host itself as a threat. Drug-free remission should follow such an intervention, representing a change in the approach to the treatment of autoimmune disease. Tolerance induction is achievable in animal models of autoimmunity but translation to the clinic has been slow. Nonetheless, progress has been made—eg, restoration of therapeutic responsiveness and drug-free remission have been achieved with stem cell transplantation in refractory autoimmunity, and significant delays in onset of type 1 diabetes in individuals at high risk have been achieved following a brief treatment with anti-CD3 monoclonal antibody. In the future, antigen-specific interventions should provide highly targeted, personalised approaches, avoiding generalised immunosuppression entirely. Such trials have already started, using both direct autoantigenic peptide administration, cellular therapies, and other modalities. In this Series paper, we discuss the history of immune tolerance induction with a focus on rheumatological disease while also highlighting essential data from other specialties. We propose key unanswered questions, which will be covered in other papers in this Series.
CD4 <sup>+</sup> CD52 <sup>lo</sup> T-cell expression contributes to the development of systemic lupus erythematosus
2018, Clinical Immunology
Citation Excerpt :
Soluble CD52 binds to siglec-10 on activated T cells, including CD4+ CD52lo T cells, which leads to the inhibition of these cells by impairing the phosphorylation of the T-cell receptor-associated kinases Lck and Zap70 [4]. An anti-CD52 antibody (alemtuzumab) has been used to treat multiple diseases: RA [13–15], non-Hodgkin's lymphoma [16,17], T-cell lymphoma [18,19], and relapsing-remitting multiple sclerosis [20,21]. The efficacy of alemtuzumab is brought about by anti-CD52 antibody-mediated lymphocytic depletion as immune ablation.
The cell-surface glycoprotein CD52 is widely expressed in lymphocytes. CD4⁺ CD52^hi T cells are functioning suppressor CD4⁺ T cells. We investigated the role of the immune regulation of CD4⁺ CD52 T cells in systemic lupus erythematosus (SLE). CD4⁺ CD52^lo T cells were increased in SLE patients, in positive correlation with SLEDAI, anti-ds-DNA antibody, and IgG concentration. Circulating follicular helper-like T cells (Tfh-like cells) were also increased in SLE, in positive correlation with CD4⁺ CD52^lo T cells. Chemokine receptor 8 (CCR8) expression in CD4⁺ CD52^lo T cells was increased. In vitro experiments using CD4 T cells of SLE patients showed that thymus and activation-regulated chemokine (TARC), a ligand of CCR8, contributed to the development of CD4⁺ CD52^hi T cells into CD4⁺ CD52^lo T cells. Our findings suggest that CD4 + CD52lo T-cell upregulation is involved in the production of pathogens by autoantibodies, and TARC may contribute to the development of SLE through an aberrant induction of CD4⁺ CD52^lo T cells.
Immunotoxicology of Biopharmaceutics
2018, Comprehensive Toxicology: Third Edition
A number of biopharmaceuticals that are marketed or in development are intentionally immunomodulatory in that they directly suppress or stimulate the immune system, while others indirectly, and sometimes unintentionally, affect immune system function. Regardless of whether immunomodulation is intentional or not, it may result in adverse consequences. Molecules that downmodulate immune responses may protect against the adverse consequences of a disease, but they also have the potential to affect how the body protects itself against infection and malignancies by impairing immunosurveillance, while agents that stimulate the immune system to help fight infection or cancer can result in autoimmunity. The testing of a biopharmaceutical should include specialized evaluation of possible immunotoxicity based on an understanding of the type of biopharmaceutical (monoclonal antibody, fusion protein, recombinant human cytokine, etc.) and its expected mechanism of action. A battery of in vitro and in vivo tests for evaluating immunotoxicity is available, and knowledge of the target and type of biopharmaceutical is essential to determine an appropriate testing paradigm. Testing may include routine or specialized assays to assess general immune status that can be incorporated into required toxicology studies or stand-alone studies and targeted assays that assess specific components of immunity or immune function (e.g., susceptibility to infection or cancer). Regardless of the intended mechanism of action, an assessment of immunogenicity should always be included due to the possibility of the biopharmaceutical eliciting an immune response in animals and/or humans, which may result in safety concerns such as loss of activity or exposure, immune-complex disease, or neutralization of endogenous proteins. Characterizing the potential immunotoxicity of a biopharmaceutical is critical for understanding the potential risk to patients of immunotoxicities resulting from immunogenicity, immunosuppression, or immunostimulation.

View all citing articles on Scopus

View full text

ORIGINAL ARTICLESHumanised monoclonal antibody therapy for rheumatoid arthritis

Abstract

J Immunol Methods

Blood

Lancet

Lancet

Manipulation of T-cell responses with monoclonal antibodies

Annu Rev Immunol

Immunotherapy of rheumatoid arthritis

Ann Rheumatol

The antiglobulin response to therapeutic antibodies

Semin Immunol

Reshaping human antibodies for therapy

Nature

Humanisation of monoclonal antibodies for therapy

Semin Immunol

The CAMPATH-1 antigen (CDw52)

Tissue Antigens

Genes associated with rheumatoid arthritis and mild inflammatory arthritis. II. Association of HLA with complement C3 and immunoglobulin Gm allotypes

Ann Rheum Dis

ORIGINAL ARTICLES
Humanised monoclonal antibody therapy for rheumatoid arthritis